About this trial
In this study, the investigators evaluate the potential efficacy of TXA alone and microneedling assisted with glutathione alone versus combination of oral tranexamic acid and glutathione-assisted microneedling in the treatment of melasma
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
• female patients
18/50 years old
facial melasma
Disqualifiers
pregnancy
lactation.
History of any bleeding,
clotting disorder
Trial design
Parallel
Treatments tested in this trial
microneedling
Devicewith one ml of topical glutathione will be done in group A and B, three consecutive sessions, will be performed by derma pen with 36 needles head, will adjusted 1.5 mm needle length and will moved on stretched skin in four directions several times till erythema and pinpoint developed before and after topical application of GTH.
Oral tranexamic acid
DrugThe patient will take oral tranexamic acid 250mg twice daily for 3 months
Glutathione
Other interventioninvestigators will use topical GSH solution in assist with microneedling to treat melasma
Treatment groups
Trial outcomes
Primary outcomes
compare reduction of Melasma Area and Severity Index (MASI) score in any treatment modalities
Secondary outcomes
identify patient's satisfaction by Patient Self Assessment
Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: